Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Daniel J. Lindner, MD, PhD, is an Associate Staff at the Taussig Cancer Institute in the Center for Hematology and Oncology Molecular Therapeutics, and in the Lerner Research Institute, Cleveland Clinic (Department of Cancer Biology), and also Assistant Professor at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University (Molecular Medicine). He is investigating the role of inositol kinases in apoptosis and developing experimental therapeutics for cancer based on cobalamins and nitric oxide.
Dr. Lindner received his BS degree from Massachusetts Institute of Technology in 1977, his MD from Georgetown University in 1981, and his PhD in microbiology from the Medical College of Wisconsin in 1996. His postdoctoral training was at the Greenebaum Cancer Center at the University of Maryland. He joined Cleveland Clinic in 1999.
In the past five years he has attracted over $2 million in funding from NIH/NCI. In 2002, he founded the Animal Tumor Core. Under his direction, the Tumor Core performs xenograft and syngeneic tumor studies for principal investigators of Cleveland Clinic and Case Western Reserve University. At age 52, Dr. Lindner has 59 publications and two U.S. patents.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 2/28/2013, Dr. Lindner has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.